In ERpos tumors, 70% (17/22) of BCSCs expressed 10-106 fold less ERA than tumor of origin (Figure 3B), while 57% of BCSCs expressed 10-103 fold more ERB than tumor of origin (Figure 3F). The gene discussed is ESR2; the disease is neoplasm.